Metabolism by N-acetyltransferase 1 in vitro and in healthy volunteers: A prototype for targeted inhibition

Journal of Clinical Pharmacology

Volumn 44, Issue 12, 2004, Pages 1405-1411

  Cantilena Jr , Louis R ^a   Katki, Aspandiar G ^b   Klecker, Raymond W ^b   Collins, Jerry M ^b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NONE

Author keywords

Drug interactions; Drug metabolism; NAT1; p aminosalicylate; Sulfamethoxazole

Indexed keywords

ACETYLSULFAMETHOXAZOLE; ACYLTRANSFERASE; AMINOSALICYLIC ACID; DRUG METABOLITE; N ACETYLTRANSFERASE 1; SULFAMETHOXAZOLE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG INHIBITION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; LIVER CELL; MALE; NORMAL HUMAN; OPEN STUDY;

ADULT; AREA UNDER CURVE; ARYLAMINE N-ACETYLTRANSFERASE; CELLS, CULTURED; CULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; FEMALE; HEPATOCYTES; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; P-AMINOSALICYLIC ACID; SULFAMETHOXAZOLE;

EID: 8744229842     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004270224     Document Type: Article

References (17)

1. Parkinson A. Biotransformation of xenobiotics. In: Klaassen CD, ed. Casarett and Doull's Toxicology: The Basic Science of Poisons. 5th ed. New York: McGraw-Hill; 1996:113-186.
2. Drayer DE, Reidenberg MM. Clinical consequences of polymorphic acetylation of basic drugs. Clin Pharmacol Ther. 1977;22:251-258.
3. Hein DVV, McQueen CA, Grant DM, Goodfellow GH, Kadlubar FF, Weber WW. Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber. Drug Metab Dispos. 2000;28:1425-1432.
4. Lang NP. Acetylation as an indicator of risk. Environ Health Perspect. 1997;105(suppl 4):763-766.
5. Badawi AF, Hirvonen A, Bell DA, Lang NP, Kadlubar FF. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res. 1995;55:5230-5237.
6. Mangum EM, Graham KK. Lopinavir-ritonavir: a new protease inhibitor. Pharmacotherapy. 2001;21:1352-1363.
7. Keogh A, Spratt P, McCosker C, Macdonald P, Mundy J, Kaan A. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med. 1995;333:628-633.
8. Kornhauser DM, Petty BG, Hendrix CW, et al. Probenecid and zidovudine metabolism. Lancet. 1989;2:473-475.
9. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA. 1986;256:1449-1455.
10. Hantson P, Wittebole X, Haufroid V. Ethanol therapy for methanol poisoning: duration and problems. Eur J Emerg Med. 2002;9:278-279.
11. Baud FJ, Bismuth C, Garnier R, et al. 4-Methylpyrazole may be an alternative to ethanol therapy for ethylene glycol intoxication in man. J Toxicol Clin Toxicol. 1986-1987;24:463-483.
12. Kharasch ED, Thummel KE, Mautz D, Bosse S. Clinical enflurane metabolism by cytochrome P450 2E1. Clin Pharmacol Ther. 1994;55: 434-440.
13. Spielberg SP. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm. 1996;24:509-519.
14. Mitra AK, Thummel KE, Kalhorn TF, Kharasch ED, Unadkat JD, Slattery JT. Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers. Clin Pharmacol Ther. 1996;59:332-340.
15. Cribb AE, Nakamura H, Grant DM, Miller MA, Spielberg SP. Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism. Biochem Pharmacol. 1993;45:1277-1282.
16. Katki AK, Klecker RW, Collins JM. Targeted inhibition of N-acetyltransferases (NAT1, NAT2) in human hepatocytes and cytosol. J Clin Pharmacol. 1999;39:973.
17. Hughes NC, Janezic SA, McQueen KL, et al. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics. 1998;8:55-66.